SAN JOSE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Laserscope , a pioneer in the development and commercialization of medical lasers and advanced fiber-optic devices, today announced that based on the use of its GreenLight PVP(TM) procedure for the treatment of Benign Prostatic Hyperplasia (BPH), Kings College Hospital NHS Trust, a leading London-based healthcare facility, won a prestigious clinical excellence innovation award from the Modernisation Agency of the United Kingdom’s socialized medicine body, or National Health Service (NHS).
Kings College Hospital demonstrated that by performing Laserscope’s PVP procedure on an outpatient basis, versus conducting the more invasive trans-urethral resection of the prostate, or TURP, procedure, the hospital was able to reduce costs and waiting times while increasing patient satisfaction and experience. In the UK, TURP generally involves long hospital stays, long waiting lists and high morbidity.
“We are very excited and encouraged by the work being done by Dr. Gordon Muir and his staff and colleagues at Kings College Hospital,” said Eric Reuter, President and Chief Executive Officer of Laserscope. “By utilizing our innovative PVP procedure to treat BPH, the hospital has clearly demonstrated the clinical efficacy and many other important benefits of PVP versus other more invasive, more costly and less effective treatment options.
“We have had considerable success in the UK’s private healthcare sector since launching our GreenLight system in 2002, but penetrating the two-tiered health-care system in the UK, as in many other countries, remains a challenge in that not only must clinical efficacy be demonstrated, but also the cost-effectiveness of the procedure as well,” said Mr. Reuter.
“We believe that the recognition and visibility Laserscope is receiving from this NHS award being granted to a world-renowned medical center such as Kings College, will help us gain a higher level of visibility and credibility for the many positive attributes of PVP, not only within the UK’s public healthcare system, but in other two-tiered health-care systems around the globe. This brings us even closer to our top priority -- ensuring that Laserscope’s GreenLight PVP, or Photo-Selective Vaporization of the Prostate, is recognized as the new worldwide standard of care for treating BPH.”
About Laserscope
Laserscope designs, manufactures, sells and services on a worldwide basis an advanced line of medical laser systems and related energy delivery devices for the office, outpatient surgical center, and hospital markets. More information about Laserscope can be found on the Company’s web site at http://www.laserscope.com/.
Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. These risks are detailed from time to time in the Company’s public disclosure filings with the U.S. Securities and Exchange Commission (SEC). Copies of Laserscope’s public disclosure filings with the SEC, including the most recent Annual Report on Form 10-K and the most recent forms 10-Q are available upon request from its Investor Relations Department.
At Laserscope: At Financial Relations Board: Eric Reuter, President & CEO Tricia Ross, Analyst/Investor Contact Dennis LaLumandiere, CFO (617) 520-7064 (408) 943-0636 Laurie Berman, General Information (310) 854-8315
Laserscope
CONTACT: Eric Reuter, President & CEO, or Dennis LaLumandiere, CFO, bothof Laserscope, +1-408-943-0636; or Analyst/Investors, Tricia Ross,+1-617-520-7064, or General Information, Laurie Berman, +1-310-854-8315, bothof Financial Relations Board, for Laserscope
Web site: http://www.laserscope.com/